AIM: To assess the role of (and intestinal metaplasia. with IMC, while and GERD show no significant association. IMC can be predicted in theory by logistic regression analysis. (infection and other environmental risk factors[3,5]. Despite the overall decline in gastric cancer, there has been a significant increase Tivozanib in the incidence of cancer of the gastric cardia[6]. The shift from distal to proximal stomach may be due to the decrease in the distal cancers. However, it has also been proposed that adenocarcinomas at the cardia represent a different entity of antral gastric adenocarcinomas[7]. Indeed, environmental factors or chemical carcinogens may be more strongly associated with cardia carcinomas compared with more distal gastric carcinoma[8]. On the other hand, the proximal gastric carcinomas differ Tivozanib from distal gastric carcinomas as they are not associated with a severe form of gastritis characterized by atrophy and/or intestinal metaplasia[9,10]. Carcinomas of the gastric cardia appear to be similar to those associated with Barretts esophagus, with which they share some demographic features[9]. Several studies indicated that obesity satisfies several criteria for a causal association with gastroesophageal reflux disease (GERD) and some of its complications, including erosive esophagitis, and esophageal adenocarcinoma[11-13]. Therefore, obesity could represent an important factor in the development of cardia carcinoma. The development of cardia carcinoma seems to be preceded by intestinal metaplasia, which is secondary to chronic inflammation[1,14-16]. However, the etiology of intestinal metaplasia of the gastric cardia (IMC) remains controversial. To our knowledge, no study has evaluated the effects of age, smoking and body weight on IMC. Thus, our aim was to set up a cross-sectional study to examine these the role of these factors, and also and GERD. To evaluate the incidence of IMC and the respective role of these factors on the development of IMC at a particular point in time, we enrolled a population of outpatients with upper gastrointestinal (GI) endoscopy scheduled for various reasons. MATERIALS AND METHODS Study design and population The study complied with the Declaration of Helsinki regarding investigation in humans and was approved by our institutional Ethics committee (Commission Centrale dEthique) (Controlled-trials.com, Number ISRCTN15324190, www.controlled-trials.com). This was an investigator-initiated study with no involvement of industry. Inclusion criteria All outpatients scheduled for an elective upper GI endoscopy were eligible for inclusion in the study. Exclusion criteria were: age < 18 years, pregnancy, patients unable to give their own consent, a previous history of upper GI surgery, severe bleeding diathesis (platelet count < Tivozanib 50?000/mm3, prothrombin rate < 50%), psychiatric diseases, allergy to lidocaine. All patients signed an informed consent form. For this study, 250 consecutive patients scheduled for upper GI endoscopy for a variety of conditions were recruited over a 2.5-year period. Among them, 217 accepted the study protocol (acceptance rate of 86%). Endoscopy was performed in the left lateral position after local anesthesia using a 10% xylocaine spray with the patient under conscious sedation using midazolam as reported previously[17]. A standard endoscopy was performed, including retroflexion in the stomach (Table ?(Table11). Table 1 Characteristics of the cohort study group Rabbit polyclonal to ZGPAT. (%) Endoscopic biopsies Each patient had 2 biopsies performed in the esophagus 2 cm above the Z-line, 4 biopsies at the esophagogastric junction, 2 biopsies in the cardia located within 10 mm below the Z-line, 2 biopsies in the fundus (greater and lesser curvature), 2 biopsies in the antrum (greater and lesser curvature), and one biopsy in the angulus. In the case of Barretts esophagus, 4 biopsies were performed every cm in the Barretts segment. All biopsy specimens were fixed in 0.5% formaldehyde solution and stained with haematoxylin eosin, Giemsa, and Gomori-aldehyde-fuschin. Two experienced GI pathologists (BH, MB), who were blinded to the clinical diagnosis, analyzed the biopsies. The Tivozanib diagnosis of IMC was reserved for patients with intestinal metaplasia detected in biopsy specimens sampled from the macroscopically normal-appearing gastroesophageal junction. Study variables and data collection As previously defined by Vakil et al[18], clinically significant GERD was diagnosed when.